It's been a banner year so far for Palvella Therapeutics Inc. (PVLA), which recently debuted on the Nasdaq, with its share price soaring by as much as 117% year-to-date.
This clinical-stage biopharmaceutical company is exclusively focused on developing transformational therapies for rare diseases with no FDA-approved treatments. Its lead product candidate is QTORIN rapamycin, currently under development for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and other serious, functionally debilitating skin diseases driven by the overactivation of the mTOR pathway. The mTOR signaling pathway is a key regulator of cell growth, proliferation, survival, and metabolism.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.